Ardelyx, Inc. — Form 10-Q Summary
Business context and reporting period
Clinical-stage biopharmaceutical company developing GI-tract-focused treatments for cardio-renal and gastrointestinal diseases. This unaudited report covers the quarter and nine months ended September 30, 2016. Ardelyx had no approved products and generated no product-sales revenue.
Financial results
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $24.0 million |
| Research and development expense | $24.9 million | $14.7 million | $68.0 million | $27.1 million |
| General and administrative expense | $4.3 million | $3.4 million | $13.5 million | $9.4 million |
| Net loss | $29.0 million | $18.1 million | $81.1 million | $12.6 million |
| Net loss per share, basic and diluted | $0.65 | $0.70 | $2.15 | $0.58 |
The 2015 nine-month revenue comprised $21.6 million of licensing revenue and $2.4 million of collaborative development revenue, both associated with AstraZeneca. The collaboration terminated in June 2015; no related revenue was recognized after the first half of 2015. Q3 2016 comprehensive loss was $29.1 million.
- At September 30, 2016, cash and cash equivalents were $160.4 million and short-term investments were $69.7 million, totaling $230.1 million, versus $107.0 million in cash and equivalents at December 31, 2015.
- Nine-month operating cash use was $66.0 million; investing cash use was $71.8 million, primarily purchases of short-term investments; financing provided $191.2 million. Cash and equivalents increased by $53.4 million.
- Total assets were $241.3 million; total liabilities were $18.4 million, including $17.6 million current liabilities. The balance sheet reports no borrowings or debt. Accumulated deficit was $182.6 million.
- Financing included a January public offering yielding approximately $80.8 million net and a July private placement yielding approximately $109.7 million net. Common shares outstanding rose from 26.0 million at year-end 2015 to 47.3 million at September 30, 2016.
- Future minimum operating lease payments totaled $8.5 million. The company reported no off-balance-sheet arrangements.
Material changes and management outlook
Operating expenses increased as Ardelyx advanced clinical development and manufacturing. Nine-month R&D expense rose 151%, mainly due to tenapanor Phase 3 programs in IBS-C and hyperphosphatemia, plus development and manufacturing work for tenapanor, RDX227675, and RDX98940. G&A increased 43%, primarily from professional services, personnel, and facilities.
Management expected Q4 2016 R&D expense to increase from Q3 levels and G&A to remain broadly consistent. It believed existing cash and investments would fund projected operating requirements for at least 12 months from September 30, 2016, while noting estimates depend on assumptions and additional financing would be needed in the future. Ardelyx had no credit facility or committed capital sources.
Pipeline, risks, and other notable items
- Tenapanor was in two Phase 3 IBS-C trials; management expected T3MPO-1 results in mid-2017 and T3MPO-2 results at year-end 2017. The first of two planned Phase 3 hyperphosphatemia trials was fully enrolled, with results expected in Q1 2017.
- For RDX227675, being developed for hyperkalemia via a 505(b)(2) pathway, management expected to start a Phase 3 trial and an onset-of-action study in Q4 2016. RDX98940 was expected to have an IND filing in Q4 2016.
- Management highlighted development uncertainty, clinical-trial and regulatory risk, manufacturing and supply dependence, competition, reimbursement and pricing uncertainty, and the possibility that additional financing may be unavailable on acceptable terms. Tenapanor’s prior hyperphosphatemia study showed higher-than-expected diarrhea and discontinuation rates at the highest doses; diarrhea and other GI effects remain relevant safety risks.
- The company noted potential Medicare payment changes for ESRD-related drugs beginning in 2024, which could pressure pricing if products are approved. It also disclosed a Fremont facility lease extension through September 2021.
- No litigation pending was identified as reasonably expected to have a material adverse effect. Management concluded disclosure controls were effective at a reasonable assurance level; no material change in internal controls was reported.
Investor verification priorities
- Verify subsequent enrollment, timing, and results for tenapanor’s IBS-C and hyperphosphatemia trials, and whether the RDX227675 and RDX98940 milestones occurred as planned.
- Assess cash burn and the assumptions behind management’s stated minimum 12-month funding runway, including future financing needs and potential dilution.
- Monitor tenapanor safety findings, particularly diarrhea-related discontinuations, and confirm whether regulators require additional studies.
- Evaluate manufacturing readiness, competitive developments, and likely reimbursement and pricing conditions for the target markets.
- Review the effects of the 2016 equity offerings and the resulting increase in shares outstanding.